Key Takeaways Strong demand drivers and pipeline expansion in chronic therapies, generics, and biosimilars are set to support long-term growth and broader international diversification. Focus on higher-margin products, operational efficiencies, and regulatory tailwinds should enhance profitability and accelerate new product approvals.Read more
